673 related articles for article (PubMed ID: 15576204)
1. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development.
Areschoug T; Carlsson F; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 2004 Dec; 22 Suppl 1():S9-S14. PubMed ID: 15576204
[TBL] [Abstract][Full Text] [Related]
2. Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein.
Carlsson F; Berggård K; Stålhammar-Carlemalm M; Lindahl G
J Exp Med; 2003 Oct; 198(7):1057-68. PubMed ID: 14517274
[TBL] [Abstract][Full Text] [Related]
3. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
4. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
6. Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway.
Carlsson F; Sandin C; Lindahl G
Mol Microbiol; 2005 Apr; 56(1):28-39. PubMed ID: 15773976
[TBL] [Abstract][Full Text] [Related]
7. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system.
Thern A; Stenberg L; Dahlbäck B; Lindahl G
J Immunol; 1995 Jan; 154(1):375-86. PubMed ID: 7995956
[TBL] [Abstract][Full Text] [Related]
8. Interaction between complement regulators and Streptococcus pyogenes: binding of C4b-binding protein and factor H/factor H-like protein 1 to M18 strains involves two different cell surface molecules.
Pérez-Caballero D; García-Laorden I; Cortés G; Wessels MR; de Córdoba SR; Albertí S
J Immunol; 2004 Dec; 173(11):6899-904. PubMed ID: 15557185
[TBL] [Abstract][Full Text] [Related]
9. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
10. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
11. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
Sandin C; Carlsson F; Lindahl G
Mol Microbiol; 2006 Jan; 59(1):20-30. PubMed ID: 16359315
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
13. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
14. Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor.
Johnsson E; Berggård K; Kotarsky H; Hellwage J; Zipfel PF; Sjöbring U; Lindahl G
J Immunol; 1998 Nov; 161(9):4894-901. PubMed ID: 9794423
[TBL] [Abstract][Full Text] [Related]
15. [Streptococcus pyogenes--much more than the aetiological agent of scarlet fever].
Stock I
Med Monatsschr Pharm; 2009 Nov; 32(11):408-16; quiz 417-8. PubMed ID: 19947304
[TBL] [Abstract][Full Text] [Related]
16. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
17. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
18. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
19. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development.
McArthur JD; Walker MJ
Mol Microbiol; 2006 Jan; 59(1):1-4. PubMed ID: 16359313
[TBL] [Abstract][Full Text] [Related]
20. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
